Pulmonary Arterial Hypertension: New and Emerging Treatment Strategies and Counseling Pearls, featuring Pharmacist-Patient Counseling Vignettes

Pulmonary Arterial Hypertension: New and Emerging Treatment Strategies and Counseling Pearls,
featuring Pharmacist-Patient Counseling Vignettes

Faculty Presenter

Rebekah H. Anguiano, PharmD, BCPS, BCACP
Clinical Coordinator, Specialty Pharmacy Services
University of Illinois Hospital and Health Sciences System
Chicago, Illinois

Clinical Assistant Professor
Department of Pharmacy Practice
University of Illinois at Chicago College of Pharmacy
Chicago, Illinois
 
Program Description
Pulmonary arterial hypertension (PAH) can be classified into 5 groups that differ in clinical presentation, pathophysiology, and hemodynamic characteristics, all of which affect treatment strategy. Because PAH is a rare disease, many clinicians may not be familiar with its symptoms, and patients with PAH frequently experience diagnostic delays, with some experiencing symptoms for more than 2 years before receiving a diagnosis. To appropriately slow disease progression and improve the prognosis of patients with PAH, it is imperative that pharmacists and clinicians follow guideline recommendations and evidence supporting use of agents. Multiple classes of drugs are approved for use in PAH as monotherapy or combination regimens, with additional potential disease-modifying agents in development. Some treatment centers have integrated pharmacy services into their clinics to facilitate communication between patients and clinicians, expanding the pharmacist’s involvement in the treatment and management of patients with PAH. With these expanding roles, pharmacists will have to become familiar with existing and emerging therapy options, drug-related adverse effects, and access and adherence issues patients face. This activity incorporates videos that will allow pharmacists to apply counseling strategies to real-world patient encounters by following a patient from treatment initiation to medication follow-up while highlighting the importance of adherence.

Target Audience:  Health-system and specialty pharmacists
Type of Activity: Application
Release date: April 14, 2021
Expiration date: April 14, 2022
Time to complete activity:  1.5 hours
Fee: Free

Educational Objectives
At the completion of this activity, participants will be able to:

• Identify pulmonary arterial hypertension (PAH) subtypes, prognostic factors, pathophysiology, and genetic contributors
• Explore different current and emerging treatment approaches to improve clinical outcomes in PAH including the use of combination regimens
• Examine the clinical efficacy, safety, dosing, administration, and real-world experience of medications to treat PAH
• Investigate the burden of medication-related concerns, such as adherence issues, access barriers, potential adverse effects, and drug interactions, as well as various strategies that can improve multidisciplinary care and quality of life for patients with PAH

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-21-027-H01-P. The activity is available for CE credit through April 14, 2022.


Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, view the webcast in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
 
Disclosures

Faculty

Rebekah H. Anguiano, PharmD, BCPS, BCACP, has no relevant financial relationships with commercial interests to disclose.

Pharmacy Times Continuing Education™ Planning Staff – Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Liza Patel, PharmD, RPh; Ann Marciano; Kelly McCormick; Susan Pordon; and Brianna Winters have no relevant financial relationships with commercial interests to disclose.

An anonymous peer reviewer is used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this live CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms